Last reviewed · How we verify

NCT03457831

Status Epilepticus in the Critically Ill Patients

Recruiting now Last updated 22 October 2020
What this trial tests

trial in Status Epilepticus in 1,000 participants. Currently enrolling.

Timeline
28 February 2018
Primary endpoint
31 December 2028
31 December 2028

Quick facts

Lead sponsorIctal Group
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment1,000
Start date28 February 2018
Primary completion31 December 2028
Estimated completion31 December 2028
Sites20 locations across France

Conditions studied

Sponsor

Ictal Group

Who can join

18 and older, any sex, with Status Epilepticus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Convulsive and Non Convulsive Status Epilepticus (SE) and Pseudo Status Epilepticus prospective registry. Data collection using a standardized form : demographic data and data related to the SE, including circumstances of onset, dates and times of onset and of seizure control, on-scene clinical findings, clinical features of the seizures, pre-hospital and hospital care providers, timing of antiepileptic and supportive treatments, results of etiological investigations, cause of SE, type and dosage of antiepileptic drugs. Dates and times of EEG monitoring, EEG results. Outcomes including vital status and Glasgow Outcome Scale score at ICU and hospital discharge, day-90 and 1-year after SE and determined based on data in the ICU and/or neurologist charts and/or patients phone interview.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Multicentre observational status-epilepticus registry: protocol for ICTAL.
    Jacq G, Chelly J, Quenot JP, Soulier P, et al · · 2022 · cited 6× · PMID 35168989 · DOI 10.1136/bmjopen-2021-059675
  2. Electrocardiographic Changes at the Early Stage of Status Epilepticus: First Insights From the ICTAL Registry.
    Chinardet P, Gilles F, Cochet H, Chelly J, et al · · 2023 · cited 3× · PMID 36533915 · DOI 10.1097/ccm.0000000000005768
  3. Management and outcomes of critically ill adult patients with convulsive status epilepticus and preadmission functional impairments.
    Vieille T, Jacq G, Merceron S, Huriaux L, et al · · 2023 · cited 1× · PMID 36803873 · DOI 10.1016/j.yebeh.2023.109083
  4. Assessment of health-related quality of life, cognitive, physical and psychological impairments in critically ill adults after status epilepticus (POSEIDON 2): protocol for a multicentre longitudinal study.
    Legriel S, Bernard C, Sboui G, Sigaud F, et al · · 2026 · PMID 41775483 · DOI 10.1136/bmjopen-2025-112563

Verify or expand the search:

Other recruiting trials for Status Epilepticus

Currently open trials in the same condition.

Other Ictal Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03457831.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing